Mesirow Institutional Investment Management Inc. Lowers Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Mesirow Institutional Investment Management Inc. decreased its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 21.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 782,451 shares of the biotechnology company's stock after selling 219,452 shares during the period. Mesirow Institutional Investment Management Inc. owned 0.33% of ADMA Biologics worth $13,419,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in ADMA. Barclays PLC raised its position in ADMA Biologics by 192.2% during the third quarter. Barclays PLC now owns 528,629 shares of the biotechnology company's stock valued at $10,567,000 after purchasing an additional 347,692 shares in the last quarter. Franklin Resources Inc. raised its holdings in ADMA Biologics by 19.4% in the 3rd quarter. Franklin Resources Inc. now owns 167,644 shares of the biotechnology company's stock worth $3,351,000 after acquiring an additional 27,180 shares during the last quarter. B. Riley Wealth Advisors Inc. bought a new position in ADMA Biologics during the third quarter valued at approximately $368,000. Lord Abbett & CO. LLC purchased a new position in shares of ADMA Biologics in the third quarter worth approximately $61,858,000. Finally, Principal Financial Group Inc. raised its stake in shares of ADMA Biologics by 785.7% in the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock worth $23,872,000 after buying an additional 1,059,394 shares during the period. Hedge funds and other institutional investors own 75.68% of the company's stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Price Performance

ADMA traded down $0.55 during trading on Friday, reaching $21.79. The company's stock had a trading volume of 1,390,333 shares, compared to its average volume of 3,623,566. The firm has a fifty day simple moving average of $18.68 and a two-hundred day simple moving average of $18.27. The company has a market cap of $5.15 billion, a price-to-earnings ratio of 77.88 and a beta of 0.53. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 1 year low of $6.26 and a 1 year high of $23.64.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.